Full-Time
Confirmed live in the last 24 hours
Develops therapies for central nervous system disorders
$100k - $150kAnnually
Senior
San Diego, CA, USA
Must live in the territory's geography.
You match the following Axsome Therapeutics Inc's candidate preferences
Employers are more likely to interview you if you match these preferences:
Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.
Company Size
201-500
Company Stage
IPO
Total Funding
$430.7M
Headquarters
New York City, New York
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Performance Bonus
Company Equity
The firm sees potential in Sarepta's Elevidys for Duchenne muscular dystrophy, Legend's ability to double its manufacturing capacity, and Axsome's anticipated launch of AXS-07 for migraines.
Captrust Financial Advisors invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).
Erste Asset Management GmbH invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).
PDT Partners LLC makes new $1.05 million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).
FORA Capital LLC makes new $994,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).
Intech Investment Management LLC makes new $983,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).
Axsome Therapeutics, Inc. (NASDAQ:AXSM) has emerged as a prominent player in the biopharmaceutical industry, focusing on developing novel therapies for central nervous system (CNS) disorders.
Castleark Management LLC invests $2.57 million in Axsome Therapeutics, Inc. (NASDAQ:AXSM).
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
Lori brings multifaceted experience in global pharmaceuticals and joins from Axsome Therapeutics, where she spent nearly five years as a member of the executive team serving as head of commercial and business development and most recently as head of product strategy.